2019 Press Releases Communiqués de presse
Sernova Announces the Appointment of Dr. David Lillicrap, M.D. to its Scientific Advisory Board
Sernova to Participate on Diabetes Panel and Present at NobleConXV, 15th Annual Investor Conference January 28th - 29th, 2019
Sernova Announces Successful Enrollment Approaching 50% of Subjects in its U.S. Phase I/II Cell Pouch Diabetes Clinical Trial
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 30, 2019 30 January, 2019
Sernova Announces the Appointment of Dr. David Lillicrap, M.D. to its Scientific Advisory Board
Sernova Adds Scientific Advisory Board Expertise as it Broadens its Therapeutic Cell Therapy Applications for
Rare Blood Diseases
January 30, 2019 9:00 a.m. EST
LONDON, ONTARIO – January 30, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) a clinical-stage
regenerative medicine company, today announced the appointment of Dr. David Lillicrap, M.D., FRCPC to its
Scientific Advisory Board (SAB).
Dr. David Lillicrap is Associate Head, Research, and Professor in the Department of Pathology and Molecular
Medicine at Queen's University at Kingston, Ontario, Canada. He holds a Tier 1 Canada Research Chair (CRC)
in Molecular Hemostasis and is a past Career Investigator of the Heart and Stroke Foundation of Ontario. In
2013, he was elected to the Fellowship of the Royal Society of Canada. Dr. Lillicrap serves as a member of the
Medical Advisory Board of the World Federation of Hemophilia. He is a member of the Council of the
International Society on Thrombosis and Haemostasis (ISTH), is a past Chair of ISTH’s Scientific and
Standardization Committee and is Co-Editor-in-Chief of the Society’s journal, the Journal of Thrombosis and
Haemostasis. Dr. Lillicrap has also been a SAB member of the Horizon 2020 HemAcure program developing a
personalized medicine approach for treatment of hemophilia of which Sernova is partner. He is an
internationally recognized expert on the molecular basis of common inherited bleeding disorders.
“We are pleased to welcome David to Sernova’s Scientific Advisory Board,” said Dr. Philip Toleikis President
and CEO Sernova Corp. “Dr. Lillicrap’s internationally recognized leadership in hematology and novel cell and
gene therapy-based applications will be instrumental as we expand the breadth and experience of our Scientific
Advisory Board in support of Sernova’s hemophilia and other rare disease programs.”
As a Canada Research Chair in Molecular Hemostasis, his program of research focuses on the molecular basis
of the hemostatic system (coagulation), with a particular emphasis on the commonest inherited bleeding
disorders, hemophilia, and von Willebrand disease. During his tenure as a Canada Research Chair, Dr.
Lillicrap’s group has achieved several research accomplishments including the establishment of a national
reference laboratory for the genetic diagnosis of inherited bleeding disorders. His research interests focus on
three key areas including von Willebrand factor pathobiology, factor VIII immunology and the evaluation of
novel gene, and cell-based strategies for the treatment of hemophilia.
About the Cell Pouch System
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long-
term survival and function of immune protected therapeutic cells. The device is designed to incorporate with
tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells
which then release proteins and hormones as required to treat disease. The device along with therapeutic cells
has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has
been proven to provide a biologically compatible environment for insulin-producing cells in humans. Within the
Horizon 2020 HemAcure program corrected human cells from subjects with Hemophilia A have been shown to
engraft within the Cell Pouch, produce Factor VIII and improve blood clotting in a preclinical model of
hemophilia A.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 28, 2019 28 January, 2019
Sernova to Participate on Diabetes Panel and Present at NobleConXV, 15th Annual Investor Conference January 28th - 29th, 2019
January 28, 2019 6:00 a.m. EST
LONDON, ONTARIO – January 28, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-
stage regenerative medicine company announced today that Dr. Philip Toleikis, President and CEO will present
the latest company overview and is invited to participate on the Diabetes Panel at NobleConXV — Noble
Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Fla., on Monday
January 28th at 11:00 a.m. Eastern Time.
The panel will cover a broad spectrum of interests involving diabetes including the discovery and
commercialization of novel diabetes therapeutics and diagnostics, diabetes research, as well as nutrition and
awareness. Included on the panel are Dr. Camillo Ricordi, Director of the Diabetes Research Institute; Dr.
Michael Castagna, CEO of MannKind Corporation; Steve Perrin, Ph.D., CEO and Founder of Anelixis
Therapeutics; William L. Rust, Ph.D., CEO and Founder of Seraxis; Michael Fox of DugalHealth; Martin Beland,
VP Marketing and Strategic Development of Inolife Sciences; Steve Glover, CEO of Variant Pharmaceuticals;
and Dr. Philip Toleikis, Ph.D., President & CEO of Sernova Corp.
A video webcast of the presentation will be available the following day on the company's website
www.sernova.com and as part of a complete catalog of presentations available at Noble Capital Markets’
Conference website (http://nobleconference.com) as well as on the new investor portal created by Noble called
Channelchek (http://www.channelchek.com).
About Sernova, Corp
Sernova, Corp., (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive
platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary
focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes,
hemophilia A and thyroid disease. Sernova is developing regenerative medicine therapeutic technologies using a
medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and
stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases
such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through
replacement of proteins or hormones missing or in short supply within the body.
For further information contact:
Danny Matthews, Senior Associate
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
For investor inquiries and media inquiries in Canada:
Dominic Gray, Corporate Communications
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Share the news Partagez les nouvelles
Press Release Communiqué de presse - January 17, 2019 17 January, 2019
Sernova Announces Successful Enrollment Approaching 50% of Subjects in its U.S. Phase I/II Cell Pouch Diabetes Clinical Trial
January 17, 2019 9:00 a.m. EST
LONDON, ONTARIO – January 17, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage
regenerative medicine company today announced the enrollment of the first three of seven subjects in its Phase
I/II trial of Sernova’s Cell Pouch™ for Clinical Islet Transplantation in type 1 diabetes.
“We are pleased to report we are on track with patient enrollment in the Sernova Cell Pouch study for type 1
diabetes,” stated Dr. Piotr Witkowski, principal investigator and Director of the Pancreatic and Islet Transplant
Program at University of Chicago School of Medicine. “The Cell Pouch System is designed to improve the
quality of life of people with diabetes and this milestone marks an important step towards building further
validation of Sernova’s innovative approach to diabetes treatment.”
Sernova is expecting to report preliminary safety data from this landmark clinical study in the first half of 2019
and preliminary efficacy data in the second half of 2019.
About the Study
The FDA allowed protocol is a Phase I/II non-randomized, open label, single arm, company-sponsored trial,
where up to seven diabetic subjects with hypoglycemia unawareness enroll into the study under informed
consent. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation
into the Cell Pouch. The secondary objective is to assess efficacy through a series of defined measures including
reduction in severe hypoglycemic events and HbA1c as well as survival of islets following transplant into the
Cell Pouch.
Study subjects will receive Sernova’s Cell Pouches including a small sentinel device implanted under the skin.
Following a defined period to allow for the development of vascularized tissue chambers within the Cell Pouch,
subjects will be stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, will
be transplanted into the Cell Pouch.
The sentinel Cell Pouch will be removed after approximately 90 days to allow for an early assessment of islet
survival in the device. Subjects will be followed for additional safety and efficacy measures for approximately
six months. At this point, a decision will be made with regard to the transplant of a second dose of purified
islets. Patients will then be further followed to assess safety and efficacy for up to one year.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more
information on enrollment and recruitment details please visit www.pwitkowski.org/sernova or contact (773)
702-2504.
About Diabetes
Type 1 diabetes is a chronic disease that affects more than 42.5 million globally, in which the body's immune
system attacks and destroys the pancreatic cells that produce insulin, an essential hormone to help the body
use glucose. To date, there is no cure for type 1 diabetes, and people living with the disease are dependent on
insulin therapy, an imperfect treatment method that requires careful monitoring throughout the day along with
multiple calculated doses of insulin to help regulate their blood sugar levels. A miscalculation or unexpected
variable leading to high or low blood sugar episodes are daily threats, and only a third of people with type 1
diabetes achieve their long-term blood glucose targets, placing them at risk for type 1 diabetes-related health
complications. Hypoglycemia unawareness, a subset of diabetes in which individuals experience a critical drop
in blood sugar without warning symptoms, represents more than 15% of type 1 diabetes population.
About the Cell Pouch
The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long-
term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly
vascularized tissue chambers for the transplantation and function of therapeutic cells which then release
proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to
provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to
provide a biologically compatible environment for insulin-producing cells in humans.
About Sernova Corp
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune
protected therapeutic cells (i.e. human donor cells, corrected human cells and stem-cell derived cells) to
improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent
diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or
hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
United States:
Danny Matthews
Solebury Trout
Tel: (646) 378-2928
dmatthews@soleburytrout.com
www.soleburytrout.com
Canada:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Ray Matthews & Associates
Tel: (604) 818-7778
ray@raymatthews.ca
www.raymatthews.ca
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not
historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,
“believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions
“will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of
future performance, and actual results may differ materially from those in forward-looking statements.
Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the
date such statements were made, which include our beliefs about the conduct and outcome of clinical trials.
Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.
Contact Us Contactez-nous
Business
development
Développement
des affaires
Dr. Philip Toleikis
Sernova Corp.
1.519.858.5184
info@sernova.com
Investor
relations
Communication
d'entreprise
Danny Matthews
Solebury Trout
1.646.378.2928
dmatthews@soleburytrout.com
www.soleburytrout.com
Corporate
communications
Communication
d'entreprise
Dominic Gray
Sernova, Corp.
1.519.858.5126
info@sernova.com
About UsL'entreprise
Company OverviewPrésentation de l'entreprise
LeadershipDirection
PartnersLes partenaires
Company MilestonesJalons de l'entreprise
Corporate GovernanceGouvernance d'Entreprise
TechnologyTechnologie
Regenerative MedicineMédecine régénérative
Cell Pouch System™Cell Pouch System™
Immune Protection TechnologyImmuno-Protection
IndicationsLes Indications
Therapeutic PipelinePipeline Thérapeutique
Clinical StudiesEtudes cliniques
PressPresse
Featured NewsNouvelles
Press ReleasesCommuniqués de presse
Latest UpdatesDernières mises à jour
News Dispatch ServiceService de Distribution de Nouvelles
InvestorInvestisseur
Financial ReportsRapports Financiers
EventsÉvénements
Analyst Coverage Couverture d'analyste
Stock PricePrix de l'action
About Sernova.com A propos de Sernova.com
Sernova Corp (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes, hemophilia A and thyroid disease. Sernova Corp (TSX-V: SVA) est une société en phase clinique (US FDA; Santé Canada) développant des applications thérapeutiques afin de traiter les maladies chroniques grâce à une approche régénérative. L’objectif principal de Sernova est de développer des technologies pour le traitement des patients atteints de diabète insulino-dépendant (T1), d’hémophilie A et de maladie de la glande thyroïde.
Please read our Legal Notice and Privacy Policy which includes information about Disclaimers and Terms of Use. Veuillez lire notre notice légale et notre politique de confidentialité, qui comprennent des informations sur les clauses de non-responsabilité et les conditions d'utilisation.
Career OpportunitiesOpportunités de carrière
See our latest job posting and long-term career opportunities: Voir nos dernières offres d'emploi et opportunités de carrière à long terme:
Career Opportunities pagePage web Opportunités de carrière
Follow us Suivez nous
All content is copyright
Tout le contenu est copyright
© 2001 - 2019 Sernova, Corp.
All content is copyright Tout le contenu est copyright © 2001 - 2019 Sernova, Corp.